{"id":"NCT04415658","sponsor":"Washington University School of Medicine","briefTitle":"Intravenous Thyroxine for Heart-Eligible Organ Donors","officialTitle":"A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible Brain Dead Organ Donors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-01","primaryCompletion":"2022-11-06","completion":"2022-12-06","firstPosted":"2020-06-04","resultsPosted":"2024-01-10","lastUpdate":"2024-01-10"},"enrollment":838,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Brain Death","Heart Failure"],"interventions":[{"type":"DRUG","name":"Thyroxine","otherNames":[]},{"type":"DRUG","name":"Saline","otherNames":[]}],"arms":[{"label":"Thyroxine","type":"EXPERIMENTAL"},{"label":"Saline Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo","primaryOutcome":{"measure":"Heart Transplanted","timeFrame":"One week","effectByArm":[{"arm":"Thyroxine","deltaMin":230,"sd":null},{"arm":"Saline Placebo","deltaMin":223,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.57"}]},"eligibility":{"minAge":"14 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":["30689222","31802716","38048188","34838132"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":419},"commonTop":["Hypertension","Tachycardia","Atrial fibrillation","Ventricular ectopy","Misc/Other"]}}